Introduction: The Client Who Cannot Tolerate What Should Help

In integrative medicine, we are trained to believe that low-dose naltrexone (LDN) is gentle. Compared to full-dose naltrexone at 50 mg, a dose of 0.1 mg or even 1 mg seems trivially small. The standard clinical teaching is "start low and go slow," which typically means beginning at 0.5 to 1.5 mg and titrating upward toward the conventional LDN range of 1.5 to 4.5 mg. For most clients, that approach works well. But there is a subset of clients for whom even these "low" doses are not low enough, and standard titration schedules are not slow enough.

This article is drawn from an educational consultation with a client recovering from occupational PTSD, post-COVID postural orthostatic tachycardia syndrome (POTS), suspected mast cell activation syndrome (MCAS), and environmental sensitivities. She had already attempted LDN twice and experienced what can only be described as an endorphin crash: debilitating fatigue, loss of all motivation, suicidal ideation timed to her hormonal cycle, and a total shutdown of normal functioning. The clinical questions that emerged from this encounter are relevant to anyone prescribing LDN for complex, multi-system illness and deserve a thorough exploration.

1. The Post-COVID Landscape: POTS and MCAS Are Everywhere

Before the COVID-19 pandemic, POTS was relatively uncommon in most clinical practices. A physician might encounter one or two cases per year. After COVID, POTS presentations are nearly routine, and mast cell activation syndrome has become what many integrative practitioners now call an epidemic in plain sight.

A 2025 study published in the European Heart Journal – Quality of Care and Clinical Outcomes analyzed data from over 65 million clients and found that the incidence rate of POTS increased from 1.42 per million to 20.3 per million person-years after the pandemic, a roughly fourteen-fold rise (Dulal D, Maraey A, Elsharnoby H, et al., 2025). Approximately 20 million individuals worldwide have developed POTS following the pandemic, and it is estimated to affect roughly 30% of highly symptomatic long-COVID clients.

MCAS has followed a parallel trajectory. While formal epidemiological data on post-COVID MCAS is still emerging, the clinical experience across integrative and functional medicine practices is overwhelming. The client in this consultation is representative: she developed POTS after COVID, had features strongly suggestive of MCAS, but did not present with the classic textbook picture of rashes, urticaria, or anaphylaxis. Her mast cell dysfunction appeared to be centered primarily in the brain.

This raises an essential clinical question. When a client fails the formal diagnostic criteria for POTS or MCAS, do they not have it? The answer requires understanding what the "S" in "syndrome" actually means.

The Meaning of "Syndrome" and the Limits of Cookbook Medicine

"Syndrome" implies that we do not know everything about the condition. It demands clinical judgment, not rigid adherence to diagnostic checklists. We do not say "breast cancer syndrome" because breast cancer is a histologically defined entity. We do say "acute coronary syndrome" because there is a spectrum of presentation before a definitive myocardial infarction is confirmed. MCAS is, by definition, a syndrome, and many clients who are told they do not have it were told so because they failed a narrow set of tests, not because they do not have the clinical picture.

The concern here extends beyond any single diagnosis. Evidence-based medicine, when applied as a rigid doctrine rather than as a guiding principle, has paradoxically made the next generation of clinicians less clinically skilled. When the only acceptable evidence is a randomized controlled trial, and the only acceptable diagnosis is one confirmed by a laboratory test, then clinical acumen withers. The art of listening to the client, recognizing patterns, and exercising judgment in the face of uncertainty is the very thing that "syndrome" demands of us.

2. When MCAS Presents in the Brain: A Different Kind of Histamine Reaction

Most clinicians think of histamine reactions as peripheral phenomena: hives, flushing, food intolerance, nasal congestion, gastrointestinal distress, or anaphylaxis. But mast cells are present throughout the central nervous system, including in the dura and the brain parenchyma, and histamine is a major neurotransmitter in the brain. When mast cells degranulate in the central nervous system, the clinical picture can look nothing like a classic allergic reaction.

In the brain, histamine excess may present as hypervigilance, insomnia, irritability, difficulty concentrating, emotional lability, a feeling of being "wired but exhausted," intolerance to sensory stimulation, and reactivation of trauma pathways. The client in this consultation could not tolerate neurofeedback, a modality that in most people is mildly irritating at worst, because it appeared to activate a central histamine cascade. Rather than simply feeling frustrated with the neurofeedback screen, she would go into full nervous system shutdown.

This is a critical teaching point. Neurofeedback uses EEG-based signals to provide feedback, often through a movie or visual display that becomes partially obscured when brainwave patterns deviate from target. In a histamine-sensitized brain, that mild irritation may not stay mild. The irritation activates the histamine pathway, which drives hyperawareness, which activates the amygdala, which opens a pathway back to stored trauma. The result is not a learning experience but a retraumatization.

Benadryl (diphenhydramine) works precisely because it is an antihistamine that crosses the blood-brain barrier. Its most famous side effect, drowsiness, is actually its mechanism of action in the central nervous system: it reduces central histamine, and the brain calms down. This is why some clients with brain-based MCAS patterns report feeling dramatically better after antihistamines and why central mast cell stabilization may be a critical therapeutic target.

3. The Intersection of Trauma, Mast Cells, Hormones, and the Nervous System

One of the most underappreciated dynamics in complex chronic illness is the bidirectional relationship between the hormonal cycle, mast cell activation, and the trauma response. Estrogen receptors (ER-α and ER-β) are expressed directly on mast cells, and estrogen binding increases mast cell degranulation in a dose-dependent fashion (Bonds RS, Midoro-Horiuti T, 2013). Meanwhile, histamine itself stimulates ovarian estrogen production, creating a vicious feedback loop: estrogen drives histamine release, and histamine drives more estrogen production.

Progesterone, by contrast, inhibits mast cell degranulation by limiting calcium influx into mast cells (Vasiadi M et al., 2006). This means that during the phases of the menstrual cycle when estrogen is high relative to progesterone, particularly around ovulation and in the late luteal phase, mast cell reactivity may surge.

For the client in this consultation, her worst symptom flares, including suicidal ideation, occurred in the context of both her hormonal cycle and LDN dose increases. She reported that at 0.2 mg of LDN, timed with her menstrual period and a viral illness, she became debilitated. When she later increased to 0.24 mg, her cycle nine days prior coincided with one of the most frightening episodes of her illness, including suicidal ideation and a feeling that something was profoundly wrong.

This is not coincidental. If estrogen is driving mast cell degranulation, and mast cell degranulation is driving central histamine release, and central histamine is reactivating trauma pathways, and LDN is simultaneously disrupting the endorphin system, then the compounding effect can be catastrophic in a vulnerable nervous system.

A prior clinical experience illustrates the estrogen-histamine connection clearly. Another client tracked her symptoms meticulously and observed that when her estrogen levels rose, her histamine reactions reliably appeared. Using vitex (chasteberry) to modulate estrogen and high-dose DIM (diindolylmethane) to promote estrogen metabolism, her symptoms decreased to approximately 25% of their former severity. They remained present but were no longer debilitating.

4. LDN Can Crash the Endorphin System: Understanding What Happened

LDN works by temporarily blocking opioid receptors, principally the mu-opioid receptor. The intended effect is an upregulation of endogenous opioid production: the body senses receptor blockade, interprets it as a deficit, and compensates by producing more endorphins, met-enkephalins, and other endogenous opioids. When the blockade lifts (typically within hours), the body now has more endorphins circulating and more receptors available, producing a net positive effect on pain modulation, immune regulation, mood, and inflammation.

But this model assumes a system with enough reserve to compensate. In a client who has spent years in survival mode, with a nervous system consumed by occupational trauma, retraumatization, post-COVID autonomic dysfunction, MCAS, and environmental sensitivities, the endorphin system may already be running on fumes. Such a client's endorphins are not being used for pleasure, motivation, or even baseline wellbeing. They are being consumed by the basic task of keeping the system alive and avoiding a serotonin or dopamine crisis.

When you add LDN to that depleted system, even at what seems like a micro-dose, the temporary receptor blockade may push an already fragile endorphin economy into frank deficiency. The result is an endorphin crash: sudden fatigue, loss of motivation, emotional numbness, worsening shutdown, and in severe cases, suicidal ideation.

The client in this consultation experienced this crash twice. The first time, she reached 0.2 mg, began feeling unwell, stopped for a week, restarted at 0.1 mg, and titrated back up. The second time, at 0.24 mg during her hormonal cycle, the crash was severe enough to include suicidal thoughts. Her prescribing nurse practitioner's response was that LDN should not be capable of causing such effects. But it absolutely can.

5. Ultra-Low-Dose LDN: Microgram-Level Dosing for the "Canary" Client

For clients who have crashed on milligram-level LDN, the answer is not to abandon LDN entirely but to reconceptualize the dose scale. The recommendation from this consultation was to restart at 1 microgram, not 1 milligram, and to increase by 1 microgram per month or even slower. This represents a dose roughly one thousand times lower than what most prescribers consider a starting dose.

The practical preparation method discussed was a volumetric dilution: take 0.1 mg of LDN (a capsule that can be obtained from a compounding pharmacy), open it, dissolve the contents in 100 mL of distilled water in a brown glass bottle, and use a 1 mL pipette to withdraw the dose. Each 1 mL of that solution contains 1 microgram of naltrexone. This preparation method is necessary because most compounding pharmacies do not compound below the microgram level.

The key principle articulated in this consultation was simple and essential: work with the body, not against it. If the body has demonstrated, through two failed LDN trials, that it will not tolerate a certain dose or a certain rate of increase, then the body is providing critical information. The correct response is not to push through but to respect the feedback and adjust accordingly.

Whatever titration timeline was used before and failed, double it. If the client increased every two weeks and crashed, increase every month. If she increased every month and crashed, consider every two months. The mantra is not "start low, go slow" but rather: start extraordinarily low, increase extraordinarily slowly, and learn from every failure.

6. How an Endorphin Crash Spills into Serotonin, Dopamine, and the HPA Axis

The endorphin system does not operate in isolation. Endorphins, serotonin, and dopamine exist in a dynamic equilibrium. When endorphins are functioning well, the serotonin system may partially reduce its output, essentially saying, "Endorphins are handling the mood and reward load; I can throttle back." Dopamine may do the same: "Endorphins are covering pleasure and motivation; I do not need to compensate."

When LDN causes an endorphin crash, the serotonin and dopamine systems are suddenly left unsupported. But neurochemical adaptation does not happen instantaneously. It may take two weeks to a month for the brain to upregulate serotonin receptor density, increase serotonin production, or compensate through dopamine pathways. During that gap, the client may experience severe symptoms that appear to come from multiple neurotransmitter systems simultaneously.

Clients who become more tearful, emotionally fragile, or prone to crying spells following an LDN crash may be experiencing serotonin-axis disruption. Clients who report an inability to feel joy, pleasure, motivation, or even normal fear and anxiety may be experiencing dopamine-axis disruption. The client in this consultation described a striking absence of all emotional valence: no joy, no fear, no anxiety, no motivation. She reported not having felt normal anxiety in ten years despite having been a highly anxious person earlier in life. This pattern strongly suggests that the dopamine system has been chronically affected.

The HPA (hypothalamic-pituitary-adrenal) axis is also involved. Cortisol is the body's universal stress responder. Any stress, including the physiological stress of an endorphin crash, can elevate cortisol. Cortisol elevation raises blood sugar. If blood sugar subsequently drops, epinephrine and catecholamines are recruited to compensate, which in turn stimulates more cortisol. This creates a cascade that can produce symptoms indistinguishable from an adrenal crisis or severe autonomic dysfunction.

7. Addressing Dopamine and Serotonin Deficits: Clinical Options

When a client reports an inability to feel joy or pleasure, the clinical question shifts to whether dopamine-system support is needed. In this consultation, the client explicitly stated that she could not feel joy, that she had zero motivation, and that her body felt completely shut down. This profile is consistent with dopamine-system dysfunction, not merely depression in the conventional psychiatric sense.

Mucuna pruriens was discussed as a natural source of L-dopa, the direct precursor to dopamine. Mucuna pruriens has a long history of use in Ayurvedic medicine and contains standardized concentrations of L-dopa. It has been studied in the context of Parkinson's disease, where dopamine deficiency is the primary pathology, and has shown clinical benefit (Katzenschlager R et al., J Neurol Neurosurg Psychiatry, 2004). For a client whose dopamine system has been compromised by chronic illness, trauma, and endorphin disruption, a carefully sourced Mucuna product may provide targeted support. The emphasis is on sourcing a clean, reputable product, as quality control in the supplement industry varies significantly.

Saffron was also discussed as a dual-action agent with evidence supporting both serotonergic and dopaminergic activity. A 2014 systematic review and meta-analysis in Human Psychopharmacology found saffron to be significantly more effective than placebo for depressive symptoms and comparable to conventional antidepressants (Hausenblas HA et al., 2013). European-sourced saffron products (such as those manufactured in Croatia, which is subject to EU quality control standards) may offer more reliable quality than domestically produced alternatives.

The clinical principle here is tool separation. If a client starts multiple supplements simultaneously and has a reaction, it becomes impossible to identify the offending agent. The recommendation was to introduce one agent at a time, wait for a clear response, and photograph or document each product for reference. This disciplined approach to supplementation is especially critical in highly sensitive clients.

8. Ketotifen: The Next Step After Foundational Stabilization

LDN was characterized in this consultation as a foundational treatment because it modulates the immune system, the nervous system, and mast cell activity through indirect pathways, primarily via TLR4 antagonism, microglial suppression, and upregulation of endogenous opioids. Because LDN does not directly target mast cells, it may be better tolerated by a hypersensitive mast cell population.

Ketotifen, by contrast, is a direct mast cell stabilizer and H1-receptor inverse agonist. It is a lipophilic compound that crosses the blood-brain barrier and can therefore reach mast cells in the central nervous system, a property that distinguishes it from many other mast cell-targeting agents. Research has demonstrated that ketotifen not only stabilizes mast cells but also functions as a microglial stabilizer by inhibiting secretory vesicle acidification, reducing the release of pro-inflammatory mediators from brain microglia (Pinke KH et al., Neurotherapeutics, 2020; Ramírez-Ponce MP et al., Life Sciences, 2023).

In clinical practice, ketotifen can be transformative for clients with brain-based MCAS patterns. However, because it directly targets mast cells, and because hypersensitive mast cells may react adversely to any direct intervention, the timing matters. The rationale for using LDN first is to calm the overall immune and nervous system environment so that when ketotifen is introduced, the mast cells are less likely to mount a paradoxical activation response.

In rare cases, ketotifen itself has triggered histamine-like reactions, presumably because direct mast cell stabilization can, in a small number of clients, provoke a transient degranulation before stabilization occurs. For the client in this consultation, whose mast cells appeared highly irritable, starting with LDN to create a less reactive baseline before introducing ketotifen was the recommended sequencing strategy.

9. The Limitations of Supplements in Severe, Multi-System Illness

A natural question in integrative medicine is whether supplements such as quercetin, vitamin C, or other natural mast cell stabilizers should be added. The teaching point from this consultation was that in severely debilitated clients with overlapping long COVID, MCAS, POTS, and hypermobility, supplements are often unreliable.

This is not an anti-supplement position. Supplements can be useful in less severe presentations and as adjunctive therapy in moderately ill clients. But in the most fragile clients, the response to supplements is inconsistent, the cost burden can be significant (particularly when insurance does not cover them), and the risk of introducing another variable into an already precarious system is real. Compounded medications such as LDN and ketotifen, while also costly, offer more targeted pharmacological action and more predictable dose-response relationships.

The exception is foundational nutritional support. Molecular hydrogen, which the client was already taking, and histamine binders such as Toxaprevent (a zeolite-based product) had provided meaningful benefit. The client reported that Toxaprevent shifted her nervous system from an intense flight response toward relative calm and improved her gastrointestinal function significantly. These responses suggest that some foundational agents may work well, but the bar for adding new supplements should be high in the most sensitive clients.

10. Hypermobility: Prevention Over Pharmacology

Hypermobility, whether as part of hypermobile Ehlers-Danlos syndrome (hEDS) or generalized joint hypermobility, is a common comorbidity in the POTS-MCAS-dysautonomia triad. The teaching point here is sobering: there is no supplement or medication that "fixes" connective tissue laxity.

The management of hypermobility is centered on injury prevention, physical therapy to strengthen the muscles that support hypermobile joints, and nutritional support for collagen synthesis (principally vitamin C and collagen peptides). The goal is not to cure the hypermobility but to reduce the frequency and severity of injuries, subluxations, and the chronic pain that often accompanies joint instability.

For clinicians, this means setting appropriate expectations. A client with hEDS who is also battling POTS and MCAS cannot expect a supplement stack to address all three conditions simultaneously. Prioritizing the conditions that are most amenable to treatment (MCAS and dysautonomia through LDN, ketotifen, and nervous system stabilization) while managing hypermobility through physical rehabilitation is a more realistic and effective strategy.

11. Thyroid Evaluation Must Go Beyond TSH

In complex chronic illness, thyroid dysfunction is frequently overlooked because the screening test, TSH (thyroid-stimulating hormone), is treated as definitive. TSH is not a direct measurement of thyroid function. It is a proxy measurement: the pituitary gland's response to circulating thyroid hormones. There are clinical scenarios where TSH appears normal but the client is functionally hypothyroid.

A comprehensive thyroid evaluation should include free T3, free T4, TPO (thyroid peroxidase) antibodies, thyroglobulin (TG) antibodies, and reverse T3. Hashimoto's thyroiditis, the most common cause of hypothyroidism in the United States, is diagnosed by elevated TPO and/or TG antibodies. It exists on a spectrum with Graves' disease, which involves thyroid-stimulating immunoglobulin (TSI).

Reverse T3 deserves particular attention. Under normal physiology, T4 is converted to T3, the more metabolically active thyroid hormone. In some clients, however, T4 is preferentially converted to reverse T3, which acts as a functional T3 antagonist. In these cases, TSH may look normal, free T4 may look normal, but the client is symptomatic because the active hormone (T3) is being blocked by its own mirror image. The only way to identify this pattern is to measure free T3, free T4, and reverse T3 simultaneously and examine the ratios.

The relevance to this client is direct. Following an endorphin crash and the systemic stress it places on the HPA axis, thyroid function may be temporarily impaired. Laboratory values obtained during or shortly after such a crash may reflect the acute disruption rather than the client's true baseline. This distinction matters for treatment decisions.

12. The Client Holds the Key: Why Observation Is Central to Good Medicine

Dr. Andrew Weil, during two years of in-person fellowship training, repeatedly emphasized a single principle: pay attention to your clients. Clients have the story, the problem, and the key. The clinician's job is to listen carefully enough to find it.

This principle was on full display in this consultation. The client had meticulously tracked her LDN doses, her cycle timing, her symptom patterns, and her response to every medication change. She knew that 0.2 mg was her threshold. She knew that her cycle and viral illness compounded the LDN effect. She knew that neurofeedback triggered shutdown rather than learning. She knew that Toxaprevent had shifted her nervous system from fight-or-flight toward calm.

None of this information would have emerged from a standard laboratory workup. It emerged because the client was observant and because the consultation created space for that observation to be heard. In an era of 15-minute visits and protocol-driven medicine, the most powerful diagnostic tool remains the client's own experience. Every symptom pattern, every timing correlation, every medication response is data, and often it is better data than any lab test can provide.

13. Redefining Progress: Reducing Burden, Not Achieving Cure

One of the most damaging expectations in chronic illness is the expectation of cure. Clients who are told they should be "better" by now, or who internalize the belief that if a treatment does not eliminate their symptoms entirely it has failed, are set up for despair.

A more realistic and ultimately more therapeutic framework is burden reduction. What would life look like with 10% less symptom burden? With 25% less? With 50% less? For a client who is currently at 100% symptom load, even a 10% reduction represents meaningful improvement in quality of life. The estrogen-modulation example described earlier illustrates this principle well: the client's histamine symptoms did not disappear entirely, but they decreased to approximately 25% of their prior severity. That 75% reduction transformed her daily functioning.

The goal is to stack small wins safely. Each intervention that produces even modest benefit adds to the cumulative effect. LDN at microgram doses may contribute 5 to 10% improvement. Hormonal modulation may contribute another 15 to 25%. Mast cell stabilization with ketotifen may add more. Brain retraining and somatic work may further lower the baseline. None of these alone is a cure, but together they can shift the balance from debilitation toward functionality.

14. Beyond "Start Low, Go Slow": A New Paradigm for Extreme Sensitivity

The standard integrative medicine teaching of "start low, go slow" is a good principle, but it is insufficient for the most sensitive clients. For these individuals, a more accurate formulation would be: start extraordinarily low, increase extraordinarily slowly, and treat every prior failure as essential clinical data rather than a reason to abandon the therapy.

The client in this consultation had two prior LDN failures. A less experienced clinician might conclude that LDN is not for her. But the failures did not indicate that LDN itself was wrong for her physiology. They indicated that the dose and the rate of titration were wrong. At 0.2 mg, her system could not compensate. At an increase rate of every two weeks, her neurochemistry could not adapt. Those are dosing failures, not drug failures.

The clinical approach moving forward includes restarting at 1 microgram (a dose roughly 200 times lower than her previous starting dose), increasing by 1 microgram at a time, allowing at least one full month between increases (and potentially longer), and supporting the process with adrenal adaptogens such as ashwagandha or rhodiola and dopaminergic support with Mucuna pruriens. Once a stable LDN dose is achieved and the immune and nervous systems have calmed, ketotifen can be introduced as the next layer of mast cell stabilization.

This is not a race. It is a negotiation with a body that has been in survival mode for years. The body will communicate clearly through symptoms, reactions, and functional capacity whether the pace is tolerable. The clinician's role is to listen and respond.

15. A Broader Perspective: Endorphins, Immunity, and Why LDN Is Worth the Effort

Before LDN was used clinically for pain, autoimmune disease, or MCAS, its therapeutic potential was explored in oncology research. Early animal studies demonstrated that opioid antagonists, including naltrexone, could modulate tumor growth. A landmark 1983 study published in Science by Zagon and McLaughlin demonstrated that naltrexone modulated tumor response in a dose-dependent manner. At a low dose producing only intermittent opioid-receptor blockade, tumor incidence in the neuroblastoma-inoculated mice fell to 33% with a 98% delay in the time before tumors appeared and a 36% increase in survival time, whereas a high dose producing continuous 24-hour blockade produced 100% tumor incidence and worse outcomes. For comparison, control animals had 100% tumor incidence within 29 days (Zagon IS, McLaughlin PJ, Science, 1983). Separately, research from Sarkar and colleagues demonstrated that enhancing beta-endorphin activity in animal models suppressed the growth and progression of several cancers, an effect mediated through activation of innate immune cells such as natural killer cells and macrophages (Sarkar DK et al., Cancer Res, 2012).

These findings underscore a principle that extends far beyond oncology. The endorphin system is not merely a feel-good mechanism. It is an immune modulator. When LDN works properly, it does not just improve pain and mood. It recalibrates the immune system's capacity to survey for threats, regulate inflammation, and maintain homeostasis. This is why LDN has shown promise across such a wide range of conditions: autoimmune disease, chronic pain, neuroinflammation, cancer, and now MCAS and long COVID.

For the client in this consultation, and for others like her, the endorphin system is both the problem and the solution. The system is depleted, fragile, and prone to crashing when provoked. But when supported carefully, at the right dose and the right pace, it has the capacity to restore a meaningful degree of immune and neurological function. The effort required to get the dosing right, even if it means starting at microgram levels and waiting months for meaningful titration, is justified by the scope of what LDN can ultimately offer.

References

Bonds RS, Midoro-Horiuti T. Estrogen effects in allergy and asthma. Curr Opin Allergy Clin Immunol. 2013;13(1):92-99.

Dulal D, Maraey A, Elsharnoby H, Chacko P, Grubb B. Impact of COVID-19 pandemic on the incidence and prevalence of postural orthostatic tachycardia syndrome. Eur Heart J Qual Care Clin Outcomes. 2025;11(5):698-704.

Hausenblas HA, Saha D, Dubyak PJ, Anton SD. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J Integr Med. 2013;11(6):377-383.

Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75(12):1672-1677.

Pinke KH, Zorzella-Pezavento SFG, de Campos Fraga-Silva TF, Mimura LAN, de Oliveira LRC, Ishikawa LLW, Fernandes AAH, Lara VS, Sartori A. Calming down mast cells with ketotifen: a potential strategy for multiple sclerosis therapy? Neurotherapeutics. 2020;17(1):218-234.

Ramírez-Ponce MP, Flores JA, Barrella L, Alés E. Ketotifen is a microglial stabilizer by inhibiting secretory vesicle acidification. Life Sci. 2023;319:121537.

Sarkar DK, Murugan S, Zhang C, Boyadjieva N. Regulation of cancer progression by beta-endorphin neuron. Cancer Res. 2012;72(4):836-840.

Vasiadi M, Kempuraj D, Boucher W, Kalogeromitros D, Theoharides TC. Progesterone inhibits mast cell secretion. Int J Immunopathol Pharmacol. 2006;19(4):787-794.

Wang X, Zhang Y, Peng Y, et al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol. 2016;173(5):856-869.

Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459.

Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science. 1983;221(4611):671-673.

About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience in integrative and functional medicine. He completed fellowship training at the University of Arizona under Dr. Andrew Weil and holds board certifications in Preventive Medicine, Medical Acupuncture, and Integrative/Holistic Medicine. He specializes in low-dose naltrexone (LDN), autoimmune disease, chronic pain syndromes, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of three books and over 20 published articles. Professional site: www.yoonhangkim.com | Clinical site: www.directintegrativecare.com